Browse Technologies

Displaying 11 - 20 of 95


New antibiotics against new targets in multi-drug resistant microorganisms

New everninomicin antibiotics including a potent bifunctional antibiotic natural product targeting two different and distant ribosomal sites are under development and can be readily produced using synthetic biology. Developing resistance to this bidentate antibiotic should be very difficult for pathogenic microorganisms.


Licensing Contact

Mike Villalobos

615.322.6751
Therapeutics
Infectious Disease

New Drug for Blood Clot: FXII Inhibitors to Treat Thrombosis

Thrombosis is the formation of a blood clot inside a blood vessel, which may cause reduced blood flow to a tissue, or even tissue death. Thrombosis, inflammation, and infections are responsible for >70% of all human mortality. Thrombosis is also the major factor for heart disease and stroke. 500,000 die from thrombosis every year in Europe. Inhibitory treatment of these conditions may also improve the outcomes of several non-fatal diseases. Researchers from Vanderbilt University and Oregon Health & Science University have jointly discovered new monoclonal antibodies that potently inhibit the blood coagulation protein factor XII (FXII), a critical player in the pathway, and anticoagulate blood. This invention provides foundation for commercial development of anti-thrombotic drugs based on new molecular entities.


Licensing Contact

Mike Villalobos

615.322.6751
Therapeutics
Antibody
Assays/Screening

New Insect Repellants Disrupt Olfactory Cues: A Strategy for Pest Protection

A multinational research team, led by Dr. L. J. Zwiebel of Vanderbilt University, has identified new compounds with potential as insect repellents. These compounds work by capitalizing on knowledge of how insect odorant receptors detect and respond to scents. Medicinal chemistry efforts have yielded a number of novel compounds that could short-circuit the insect olfactory system, essentially by over-stimulation, to effectively mask attractive odors. These compounds could be used to repel nuisance and disease-carrying insects away from humans and animals, as well as repel agricultural pests from crops or food storage facilities. Vanderbilt University is seeking commercial partners to develop the technology for agricultural uses.


Licensing Contact

Chris Harris

615.343.4433

Vascular Restoration Therapy with Cell-Penetrating CRADD Protein

Vascular inflammation caused by metabolic, autoimmune, and microbial insults mediates cardiovascular diseases that include hypertension and atherosclerosis (heart attacks, strokes), systemic lupus, and giant cell arteritis. An estimated 35 million Americans have hypercholesterolemia, contributing to 500,000 deaths underlying heart attacks and strokes. In these diseases, metabolic, autoimmune, and microbial insults continually challenge blood and vascular cells by triggering signaling to the nucleus mediated by BCL10. Genetic ablation of BCL10 rescues animals from atherosclerosis, aortic aneurysms, and fatty liver and insulin resistance due to overnutrition. Intracellular therapy with CP-CRADD is designed to extinguish BCL10-mediated noxious signals to avert vascular inflammation and its life-threatening complications including ruptured aneurysms in aorta and brain.


Licensing Contact

Mike Villalobos

615.322.6751
Therapeutics

Trackerless Image-Guidance Using a Surgical Microscope

Researchers at Vanderbilt have developed a new image-guided, trackerless surgical microscope system to be used in soft tissue surgeries. The current method is to use a surgical microscope along with an image-guided system. This new design eliminates the need for a separate image-guidance system; the entire guidance environment can be realized within the microscope environment.


Licensing Contact

Philip Swaney

615.322.1067

Inventors

Michael Miga

PosiSeat(TM): Assured Seating of Threaded Surgical Components

Vanderbilt presents an intraoperative device for taking the guesswork out of whether or not a threaded component is securely affixed to bone. This device is an anchor driver that automatically releases upon proper seating of the anchor on the bone of interest.


Licensing Contact

Taylor Jordan

615.936.7505

Image Guidance System for Breast Cancer Surgery

Vanderbilt researchers have developed an image guidance system that aims to reduce the revision rate for breast conserving surgeries through the use of intraoperative tumor location. The platform integrates MRI imaging, optical tracking, tracked ultrasound, and patient specific biomechanical models to provide a superior tumor localization end result.


Licensing Contact

Philip Swaney

615.322.1067

A Simple and Highly Portable Flow Phantom for Doppler Ultrasound Quality Measurements

A new phantom has been designed in which Doppler ultrasound measurements can be conducted for quality assurance purposes. The phantom is highly portable, does not require power to operate, and allows for simple and reproducible measurements of Doppler ultrasound function. This combination of advantages allows for realistic monthly, weekly, even daily Doppler QA measurements.


Licensing Contact

Chris Harris

615.343.4433
Medical Imaging

Breast Tumor Margin Detection System Using Spatially Offset Raman Spectroscopy

Vanderbilt University researchers have developed a technology that uses spatially offset Raman spectroscopy to obtain depth-resolved information from the margins of tumors. This helps to determine positive or negative tumor margins in applications such as breast lumpectomy, and the technology is currently being investigated for breast cancer margin detection.


Licensing Contact

Ashok Choudhury

615.322.2503

COX2 Probes for Multimodal Imaging

Inventors at Vanderbilt University have developed a novel chemical design and synthesis process for azulene-based COX2 contrast agents which can be used for molecular imaging, via a variety of imaging techniques. These COX2 probes can be utilized for numerous applications, including imaging cancers and inflammation caused by arthritis and cardiovascular diseases. The process for developing these COX2 contrast agents has been significantly improved through a convergent synthesis process which reduces the required steps to establish the COX2 precursors.


Licensing Contact

Masood Machingal

615.343.3548
Medical Imaging